TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05702710

Intervention type: OTHER
Intervention: Surgery (PIRS)
Description: Laparoscopic procedure for repair of inguinal hernia as described in:~1) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889.
Study: NCT06563375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101
Description: Given by mouth
Study: NCT05141890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Plantarum
Description: Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
Study: NCT05907850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Commercially available source of riboflavin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule compounded to be similar in appearance to the active intervention
Study: NCT05249972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Description: Topical cutaneous spray
Study: NCT06477302

Intervention type: BEHAVIORAL
Intervention: Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)
Description: Patients will be given a measurement instrument to determine the level of therapeutic adherence.
Study: NCT04990219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - capsule
Study: NCT05010304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Two-dose amoxicillin challenge
Study: NCT05249972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Description: Topical cutaneous spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Description: Topical foam
Study: NCT06113406

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Training
Description: Active Comparator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Experimental
Study: NCT05839938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D (2000IU/day) for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05249972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Description: Topical foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Description: Topical foam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cutaneous spray
Study: NCT04698590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront Guided Scleral Lenses
Description: Custom wavefront guided, higher order aberration correcting scleral lenses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Scleral Lenses
Description: Traditional scleral lenses
Study: NCT05249972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo cutaneous spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cutaneous spray
Study: NCT06234748

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will undergo 2 phases of RT replanning:~1. Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume_2 wks+ MTV3_2 weeks)+ 3mm margin.~2. Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV_2 wks + MTV3_4wks)+ 3mm margin~3. Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Standard of care therapy, weekly, with either Cisplatin or Carboplatin
Study: NCT05985694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD17002
Description: The investigational intranasal pharmaceutical product named AD17002 contains a detoxified Escherichia coli heat-labile enterotoxin, LTh(αK).~Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD17002
Description: The investigational intranasal pharmaceutical product named AD17002 contains a detoxified Escherichia coli heat-labile enterotoxin, LTh(αK).~Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
Study: NCT04729608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is an experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is the standard of care, background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is the standard of care, background therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05005819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] APN-1607
Description: Subjects will undergo PET imaging using \[18F\]APN-1607.
Study: NCT05279092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Liposomal Bupivacaine
Description: Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Description: Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
Study: NCT04678830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab (700mg)
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT06553391

Intervention type: DRUG
Intervention: The tetralogy of medication regimen
Description: During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment.
Study: NCT04649489

Intervention type: DRUG
Intervention: Atezolizumab
Description: atezolizumab 1200mg and bevacizumab 15mg/kg

Intervention type: PROCEDURE
Intervention: Surgery
Description: hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
Study: NCT05999279

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
Study: NCT06333951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT06020482

Intervention type: OTHER
Intervention: Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity
Description: The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.

Intervention type: OTHER
Intervention: Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity
Description: The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.

Intervention type: OTHER
Intervention: Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity
Description: The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
Study: NCT05488886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Aronia Berry Powder Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia Berry Extract Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phospholipid-Polyphenol Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Polyphenol Control Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
Study: NCT05890508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture
Description: Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation.
Study: NCT04682028

Intervention type: OTHER
Group type: OTHER
Intervention: professional care
Description: The trained nurses provide professional care for the patients.

Intervention type: OTHER
Group type: OTHER
Intervention: coventional care
Description: nurses provide coventional care for the patients.
Study: NCT06333951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT06006091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Different endothelial preparations according to groups, see arm descriptions for details
Study: NCT06003608

Intervention type: DEVICE
Intervention: Fluid biopsy capsule
Description: Ingestion of two SIMBA capsules

Intervention type: DEVICE
Intervention: Fluid biopsy capsule
Description: Ingestion of two SIMBA capsules

Intervention type: DRUG
Intervention: Levodopa-Carbidopa Immediate Release
Description: Single dose, Levodopa-Carbidopa Immediate Release
Study: NCT05949203

Intervention type: DRUG
Intervention: Cabotegravir Injection
Description: Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
Study: NCT05305989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg QD
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg BID
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 400 mg QD
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study: NCT05835115

Intervention type: DIAGNOSTIC_TEST
Intervention: A deep learning-based myopia and myopic maculopathy detection and prediction system
Description: This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.

Intervention type: DIAGNOSTIC_TEST
Intervention: A deep learning-based myopia and myopic maculopathy detection and prediction system
Description: This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.

Intervention type: DIAGNOSTIC_TEST
Intervention: A deep learning-based myopia and myopic maculopathy detection and prediction system
Description: This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
Study: NCT05341518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscapularis repair
Description: To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
Study: NCT06069986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft CABG
Description: comparison between onpump and off pump CABG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft CABG
Description: comparison between onpump and off pump CABG
Study: NCT05102266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1016C
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1016C
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1016D
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1016D
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT04543513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)
Description: Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
Study: NCT04552886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TH-1 Dendritic Cell Immunotherapy
Description: Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TH-1 Dendritic Cell Immunotherapy
Description: Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
Study: NCT06333951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered PO
Study: NCT04301687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Articular Branch Block
Description: Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Block
Description: Subcutaneous injection of 1ml normal sterile saline
Study: NCT05974280

Intervention type: DRUG
Intervention: Alofisel
Description: Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease

Intervention type: DRUG
Intervention: Fat stem cell
Description: mesenchymal stem cells from adipose (fat) tissue injection
Study: NCT06035874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bempedoic acid
Description: Patient willl be randomized 1:1 in both the arms
Study: NCT06558123

Intervention type: PROCEDURE
Intervention: block
Description: Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block

Intervention type: PROCEDURE
Intervention: block
Description: Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
Study: NCT04399941

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venography
Description: The venography will be performed as part of the patient's standard of care. The dialysis access will be punctured upstream of the arteriovenous anastomosis in AVF or AVG using a 4-F coaxial access set (Micro- puncture; Cook, Inc, Bloomington, Indiana). The contrast will be injected intravenously by a pump with 200 psi and a bolus of 2m/sec for total of 5 ml during upper extremity vein filming and 10 ml of contrast bolus by 3 ml/s during central vein filming while holding the breath in inspiration in anterioposterior plane.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Description: IVUS will be performed through the same sheath of the coaxial access set using an Eagle Eye Platinum RX digital catheter 7F over a compatible guidewire under fluoroscopic guidance. The lesion will be estimated fluoroscopically from the marker IVUS catheter in the vein and the cranial and caudal margins of stenotic lesion will be directly visualized during pullback of the IVUS catheter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image processing
Description: Image processing will be performed by two radiologists in a blinded manner on the images devoid of personal identifier. An adjudication committee will oversee the process and confirm their findings in case of a discrepancy.
Study: NCT06135792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arginine
Description: See arm description

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description